News Summary

Founded by Brad Sorenson in 2015, Calgary-based Providence Therapeutics was initially focused on developing mRNA-based medicines for cancer treatment, inspired by Sorenson’s son Adam’s battle with glioblastoma multiforme (GBM). As the COVID-19 pandemic hit, the company pivoted to developing a COVID-19 vaccine, partnering with Everest Medicines, which brought significant funding. Despite the pandemic pivot, Providence remains committed to oncology, with Adam now benefiting from an experimental vaccine administered under Health Canada’s compassionate care program. Sorenson is now leveraging Australia’s more flexible regulatory framework to expedite clinical trials and aims to make Providence self-sustaining within three years while maintaining a mission-driven approach.